# OnCo record idea-tr2-contribution-of-components-mandate (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-tr2-contribution-of-components-mandate/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-tr2-contribution-of-components-mandate" ;
  schema:name "No accelerated approval for a combination without proof each part contributes"@en ;
  schema:description "Regulators should refuse to approve a two-drug combination unless there is evidence that both drugs are doing something, so patients are not exposed to useless extra toxicity and cost."@en ;
  schema:url <https://onco.cc/ideas/idea-tr2-contribution-of-components-mandate/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.cell.2017.11.009> ;
  onco:related <https://onco.cc/pairings/tigit-plus-pd1-caution/> ;
  onco:drugs <https://onco.cc/drugs/tiragolumab/>, <https://onco.cc/drugs/epacadostat/> ;
  onco:terms <https://onco.cc/terms/accelerated-approval/> ;
  onco:trials <https://onco.cc/trials/impassion131/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-combination-space/>, <https://onco.cc/bottlenecks/b-incentive-misalignment/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-palmer-cell/> .